We expect Biogen (BIIB) to beat expectations when it reports third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company beat earnings expectations by 32.0%.The Zacks Consensus Estimate for sales and earnings is pegged at $2.44 billion and $3.80 per share, respectively.Factors to Consider for BiogenIn the third quarter, lower sales of multiple sclerosis (“MS”) drugs and spinal muscular atrophy drug, Spinraza, are likely to have been partially offset by revenues from ...